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Background: There were many treatments for hepatocellular carcinoma with portal vein tumor thrombus (PVTT), in
which targeted anti-angiogenic drug therapy is becoming a popular research topic. However, an objective and
non-invasive method that can evaluate the treatment effects is still lacking.
Methods: Eighteen New Zealand white rabbits implanted with VX2 tumor thrombus in portal vein were randomly
assigned into 3 groups: Endostar, saline, or control, six in each group. Multi-slice CT (MSCT) perfusion scanning was
performed to measure the differences in blood flow (TBF), tissue blood volume (TBV), and capillary permeability
time the surface (PS) before and after Endostar treatment, between Endostar and saline treatment. Two weeks after
treatment, both Endostar and saline groups underwent CT perfusion scan. The rabbits then were sacrificed by air
embolism, and specimens of tumor thrombosis were collected. Immunohistochemistry assay was also performed to
compare the expression of vascular endothelial growth factor (VEGF) in PVTT after Endostar, saline and placebo
treatment.
Results: In Endostar group, PVTT CT perfusion parameters (TBF, TBV, PS) significantly decreased after the treatment
(p <0.05). Post-treatment PVTT CT perfusion parameters (TBF, TBV, PS) were significantly lower in Endostar group
than in Saline group (p <0.05). VEGF is mainly expressed in cytoplasma. After Endostar treatment, the expression of
VEGF in PVTT was markedly reduced. There was also significant difference on post-treatment VEGF protein expression
measured by Immunohistochemistry assay between Endostar group and control group (p <0.05). Post-treatment PVTT
CT perfusion parameters (TBF, TBV, PS) were positively correlated with VEGF protein expression in all 3 groups
(rs > 0, p <0.05).
Conclusions: Multi-slice CT perfusion imaging can evaluate the anti-angiogenic effects of Endostar for the VX2
tumor thrombus in portal vein, and provide quantitative functional information.
Keywords: Tomography, Perfusion imaging, Portal vein tumor thrombus, VX2 tumo, Endostar, Antiangiogenic
treatment, DCE-CTBackground
Primary hepatocellular carcinoma is one of the most com-
mon gastrointestinal cancers. Having portal vein tumor
thrombus (PVTT) is considered one of the main indicators
for poor prognosis in liver cancer due to higher likelihood
of intrahepatic and distant metastasis [1]. Current treat-
ments for hepatocellular carcinoma with PVTT include* Correspondence: leizhen2012@yahoo.cn
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unless otherwise stated.surgery, chemotherapy, and interventional therapy, in
which targeted anti-angiogenic drug therapy is becom-
ing a popular research topic. Endostar is the generic
name for recombinant human endostatin injection agent.
It binds to the VEGF receptor on the tumor vascular epi-
thelial cells, inhibits tumor angiogenesis, and blocks nutri-
ent supply to tumor cells. However, current evaluation of
treatment effect for PVTT is generally based on patients’
median survival, an objective and non-invasive method
that can evaluate the treatment effects is still lacking [2,3].
Multislice spiral Computed Tomography (CT) perfusiond. This is an Open Access article distributed under the terms of the Creative
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fusion and reflects focal changes of vascularization. The
technique enables functional mapping of several perfusion
parameters with a spatial resolution greater than that what
can be achieved with other imaging techniques, and is
able to indicate the changes in tissue perfusion parameters
prior to the morphological alteration [4-6]. Therefore, in
this study, we investigated the relationship between tumor
growth and the changes in the portal vein tumor thrombus
tissue perfusion parameters, analyzed the changes in PVTT
CT perfusion parameters before and after Endostar treat-
ment, to provide guidance for clinical evaluation of tar-
geted antiangiogenic therapy for PVTT.
Methods
Animals
Nineteen New Zealand white rabbit, aged 4–5 months,
2.5 to 3.0 kg of body weight, 10 males and 9 females, were
provided by the Laboratory Animal Center of Liaoning
Medical College. The study was approved by Animal Protec-
tion Committee of Liaoning Medical College and conforms
to the provisions of the Declaration of Helsinki (as revised
in Tokyo 2004).
Preparation of VX2 cell line
VX2 tumor cells were provided by Professor Lei Zhen
(Department of Radiology, No. 1 Affiliated Hospital of
Liaoning Medical College, Jinzhou, China). The VX2 tumor
is a hypervascular tumor. The recovered tumor cells were
inoculated into the muscle at rabbit’ groin area. After 14
days, a solid mass was palpable at the inoculation site. The
tumor was then dissected under anesthesia. Growing tissue
at the edge of the mass was collected and placed in the petri
dish filled with saline. After removing necrotic and fibrous
tissue, tumor tissue was cut into 1.3 mm × 1.3 mm × 4 mm
size pieces, placed in saline, and extracted with 1-ml syringe
connected with 14G needle (diameter of 1.54 mm) during
the experiment.
Building portal vein VX2 tumor thrombus model
The rabbits were on fasting the night before the surgery.
At the day of operation, 0.4 ml of Sumianxin (the com-
pound solution of DHE hydrochloride, Dimethylaniline
and haloperidol, Changchun veterinary medicine Inc.,
Changchun, China) was given through intramuscular in-
jection. After hair removal, the surgery area was disin-
fected with 75% alcohol. A 5 cm incision was cut at
Epigastric area under the xiphoid to open the abdominal
cavity and expose the liver and stomach. The liver tissue
was pulled aside to find the main portal vein, and the
tumor tissues were then injected into the portal vein.
The injection site was pressed with gelatin sponge for
about half a minute after withdrawal of the needle. Once
the bleeding was stopped, chloramphenicol liquid wassprayed and the abdominal cavity was closed. Chloram-
phenicol was then given through intramuscular injection
for three days after the surgery. The tumor tissue pos-
ition and size were the same for each experimental
rabbit.
Study group assignment
Two weeks after the model development, contrast en-
hanced CT scan was performed at both arterial and ven-
ous phases with the followings scan parameters: 100
mA, 80 Kv, to confirm the formation of portal vein tumor
thrombus. Iohexol (350 mg/ml, GE Pharmaceutical Co.,
Ltd., Shanghai, China) was injected into the ear vein at
the rate of 0.5 ml/s with a high-pressure syringe before
scanning. PVTT was confirmed by enhanced CT scan.
The 18 rabbits with successful PVTT model were then
randomly assigned into Endostar (15 mg/3 mL/vial,
Yantai Bioengineering Co., Ltd., Yantai, China, provided
by Professor Lei Zhen), Saline or control group. The
rabbits assigned to control group were immediately
sacrificed by air-embolus technique, and the samples of
portal vein VX2 tumor thrombus were collected to
measure the level of vascular endothelial growth factor
(VEGF) expression prior to the Endostar treatment.
Perfusion multi-slice spiral CT scanning
GE light speed 16-perfusion scan was performed for
each rabbit. The scanning parameters were set at 100
mA, 80 kV, and center layer of the tumor at upper ab-
dominal region was selected for dynamic scanning. Be-
fore the scanning, iohexol (350 mg/ml) was injected into
the ear vein with high-pressure syringe at the dosage of
1.0 ~ 1.5 ml per kg of body weight and at the rate of 0.5
ml/s. The scan started 5 s after the injection of the con-
trast agent, and the exposure time was 50 s. After the
scan, data were sent to ADW4.2 workstation through
the LAN and analyzed using GE's Perfusion 3 liver perfu-
sion software. The abdominal aorta was identified as the in-
put artery, and portal vein was identified as the input vein.
Pseudo-color functional imagines were generated by the
computer, and the region of interest (ROI) was positioned
at the PVTT to measure perfusion parameters around the
PVTT: tissue blood flow (TBF, ml/100 ml/min), tissue
blood volume (TBV, ml/100 ml); capillary permeability time
the surface (PS, ml/100 ml/min). The ROIs along the mar-
gin of the tumor thrombus were selected based on the fol-
lowing criteria: the marginal zone of the tumor’s largest
layer with high intensity, excluding the blood vessels, nec-
rotic tissue and artifacts to minimize the partial volume ef-
fect on the measurements of perfusion parameters. The
parameter values were measured on the mean of the par-
ameter for each pixel inside the ROI. For each layer, at least
3 ROIs were selected, and for each rabbit, at least 2 layers
were measured.
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The standard human dose for Endostar is 15 mg/m2/day.
After conversion from human (60 kg) to rabbit, the dose
used in this study was 45 mg/m2/day, calculated based
on the Meeh-Rubner formula: A = k × (W2 / 3) / 1000,
where A is the body surface area (m2), W is the weight (g),
K is a constant, 10.1 for rabbit. A rabbit with the weight of
3 kg has the body surface area of approximately 0.21 m2.
The daily dose of Endostar for each rabbit was 9.45 mg,
administrated with 100 ml saline. For Endostar and saline
group, from the 3rd week each rabbit was given either
Endostar (9.45 mg/100 ml) or 100 ml saline by infusion
through ear vein. They were then closely monitored for
potential drug-related adverse reaction, which might result
in slower infusion or stopping administration. At the end
of 4th week, GE Light Speed CT perfusion scan was per-
formed to measure PVTT perfusion parameters (TBF,
TBV, PS). After the scan, rabbits were sacrificed by air-
embolus technique and the specimens of VX2 tumor
thrombus were collected.
Immunohistochemistry assay
Tissue specimens from all 3 groups were fixed with 10%
formalin, embedded with paraffin, and cut into 5 μm thick
slices. Immunohistochemistry assay was performed to de-
termine the expression level of VEGF in tumor thrombus.
Immunohistochemistry staining was conducted according
to the kit instruction. The concentration of VEGF anti-
body was 1:300. VEGF positive staining was primarily
found in the cytoplasm or cell membrane. For each slice,
5 high power fields (hpf) were randomly selected; semi-
quantitative integral method [7] was used to determineFigure 1 Venous phase contrast enhanced CT scan of PVTT. Note: the
and mild enhancement of xenograft tumor could be observed, indicating sthe results. The final score was calculated based on the
staining intensity and the percentage of positive cells
among the total number of tumor cells. Staining intensity
was scored as follows: 0 for colorless, 1 for amber, 2 for
brown, and 3 for tan. The number of positive cells was
scored as follows: 0 if less than 10% of the total cells, 1 if
10% to 20%, 2 if 21% to 50% and 3 if greater than 50%.
The scores for staining intensity and positive cells were
then added together to determine the final result: negative
if total score was 0, weak positive (+) if 1–3, moderately
positive (++) if 4–5, strongly positive (+++) if the total
score was greater than or equal to 6. The evaluation was
independently performed by 2 pathologists who were
blinded to group assignment.
Statistical analysis
All data were analyzed with SPSS (V17.0). The quantita-
tive data were summarized with mean ± standard devi-
ation, and 95% confidence interval. Perfusion parameters
between two groups were compared using t-test. The
level of VEGF protein expression was compared using
the Wilcox on rank sum test. The relationship between
PVTT CT perfusion values and VEGF protein expres-
sion was analyzed with Spearman rank correlation ana-
lysis. Analysis of variance was used to compare perfusion
parameters among all three groups, and p <0.05 was de-
fined as statistically significant.
Results
Tumor transplantation and pathology
The success rate of tumor transplantation was 94.4%
(one rabbit died from excessive bleeding due to thered arrow showed expansion of the portal vein, in which filling defect
uccessful tumor implantation. CT: Computed Tomography.
Figure 2 HE staining of rabbit portal vein VX2 tumor thrombus (Figure 2A), PVTT VEGF protein expression in control group, post-treatment
Endostar and saline group (×400) (Figure 2B, 2C, 2D). Note: VEGF was mainly expressed in the cytoplasm of cancer cells and on the envelope of
tumor cells. The level of VEGF protein expression was scored based on staining intensity and number of positive cells. In Figure 2-A, the arrow indicates
cancer cells characterized by irregular shape, karyomegaly, anachromasis, and heteromorphism. Figure 2-B is the VEGF staining image of tumor thrombus
in control group before treatment (×400). White arrow indicates VEGF expression in the cytoplasm with a score of 8 points. Figure 2-C is VEGF staining
image of tumor thrombus in saline group (×400). White arrow indicates VEGF are widely expressed in the cytoplasm of cancer cells, some of which are
deeply stained, with a score of 9 points. Figure 2-D is VEGF staining image of tumor thrombus in Endostar group after treatment (×400). The arrow
indicates VEGF expression in cytoplasm of cancer cells, characterized by lighter stain and less positive cells, with a score of 2 points. PVTT post-treatment
VEGF protein expression in Endostar group (Figure 2-D) was significantly lower than that in saline group (Figure 2-C), and also lower than pre-treatment
TBF: tissue blood flow. As shown in control group (Figure 2-B). HE: Hematoxylin eosin. BF: blood flow. TBV: tissue blood volume. PVTT: portal vein tumor
thrombus. VEGF: vascular endothelial growth factor.
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was added). Two weeks after the implantation of portal
vein VX2 tumor thrombus, venous phase enhanced scan
showed strip-shaped filling defect in portal vein (Figure 1).
Tumor cells under low magnification demonstrated nest-
or diffuse-like distribution, with infiltrative growth pat-
tern. Marginal and interstitial areas were rich in blood
vessel, showing karyomegaly and an achromas is with
obvious atypia. Under high magnification, tumor cells
had larger volume, round, fusiform or irregular shape, less
cytoplasm, large and deeply stained nuclei, and even more
obvious atypia and karyokinesis (Figure 2-A). Pathology
results confirmed the growth of cancer cells in PVTT in all
groups and there was no significant difference on patho-
logical findings between groups in the light microscope.Table 1 Baseline PVTT perfusion parameters by treatment gro
Parameter Endostar Saline
TBF (ml/100 ml/min) 345.07 ± 46.29 350.21 ± 20
TBV (ml/100 ml) 12.72 ± 2.56 11.24 ± 1.36
PS (ml/100 ml/min) 41.44 ± 5.27 42.58 ± 5.84
Note: TBF: tissue blood flow; TBV: tissue blood volume; PS: permeability surface; PVTPerfusion parameters in Endostar and saline groups
CT perfusion parameters were measured at the mar-
ginal region of the PVTT in each group. Prior to treat-
ment (baseline), there was no statistically significant
difference between 3 groups on the results of TBF,
TBV and PS (p > 0.05) (Table 1). After the treatment
(Table 2), in Endostar group (Figure 3-D, 3-E, 3-F), all
three parameters significantly decreased (P <0.05) from
the baseline (Figure 3-A, 3-B, 3-C). Before and after
treatment, Time-density curve of PVTT perfusion scan
was also obtained (Figure 4-A, 4-B). After Endostar treat-
ment, peak of PVTT perfusion decreased over time. Post-
treatment CT perfusion measurements were also lower
(P < 0.05) in Endostar group than those in saline group
(Table 3).ups (n = 6)
Control F p
.36 347.83 ± 36.60 3.21 >0.05
12.90 ± 1.90 3.60 >0.05
40.67 ± 4.38 3.52 >0.05
T: portal vein tumor thrombus.
Table 2 PVTT perfusion parameters before and after Endostar treatment (n = 6)
Parameters Before Endostar treatment After Endostar treatment t P value
TBF (ml/100 ml/min) 345.07 ± 46.29 274.55 ± 26.99 17.48 0.00
TBV (ml/100 ml) 12.72 ± 2.56 7.11 ± 0.45 6.73 0.01
PS (ml/100 ml/min) 41.44 ± 5.27 32.68 ± 2.99 2.62 0.047
Note: TBF: tissue blood flow; TBV: tissue blood volume; PS: permeability surface; PVTT: portal vein tumor thrombus.
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VEGF protein Expression was mainly shown in the cyto-
plasm and envelope of tumor cells. Occasionally, VEGF
protein Expression can also be seen in fibroblasts, mac-
rophages, endothelial cells and collagen fibers in tumor
interstitial (Figure 2). In Endostar group, the results of
post-treatment VEGF protein Expression were 1 +++, 1 ++
and 4 +, while there were 4 +++, 2 ++ in saline group and
2 +++, 4 ++ in control group. The VEGF protein Expres-
sion from control group (Figure 4-B) was used to estimate
the pre-treatment (baseline) level of VEGF protein Ex-
pression in Endostar group. After Endostar treatment,
the PVTT VEGF protein Expression (Figure 2-D) was
significantly reduced and lower than that in the saline
group (Figure 2-C).The relationship between PVTT CT perfusion results and
VEGF protein expression
There was positive correlation between PVTT CT per-
fusion values and VEGF protein Expression level inFigure 3 PVTT CT perfusion images before and after Endostar treatm
(Figure 3-C); PVTT post-treatment TBF (3-D), TBV (Figure 3-E), PS (Figure 3-F
state (red), Figure 3-B, 3-E tumor region showed high blood perfusion state
state (red). Post-treatment perfusion parameters were significantly lower thancontrol, post-treatment Endostar and saline group
(Table 4).
Discussion
Park et al. [8] confirmed that VEGF was seen in both
liver cells and HCC cells. The degree of VEGF protein
Expression was associated with the level of angiogen-
esis and cell proliferation capacity. However, to meas-
ure the angiogenic activity using VEGF level, cancer
tissue samples are required, and the test is also compli-
cated and time-consuming. In addition, the results can
only reflect the status of angiogenesis in a small por-
tion of the tumor, rather than the entire tumor, not
even mentioning the dynamic observation. Further-
more, for cancer patients who are in advanced stage
and miss the chance of operation, the status of tumor
angiogenesis cannot be measured with this approach
due to the lack of histopathological evidence [9]. On
the other hand, CT perfusion imaging as a functional
imaging modality, can not only reflect the subtle struc-
tural and morphological changes of the tissues andent. Note: PVTT Pre-treatment TBF (Figure 3-A), TBV (Figure 3-B), PS
). Figure 3-A, 3-D tumor region demonstrated high blood perfusion
(red), Figure 3-C, 3-F tumor region demonstrated high blood perfusion
those at baseline. There was no notable change on tumor size.
Figure 4 Time-density curves for the Aorta, Portal Vein, and PVTT respectively. Note: Figure 4A: Time-density curves before Endostar
treatment. Curves from multiple ROIs of PVTT showed uniform pattern, suggesting the selected ROIs represented the PVTT well. Figure 4-B: after
Endostar treatment, the peak of PVTT perfusion decreased over time when compared to before the treatment. TBF: tissue blood flow. TBV:
tissue blood volume. PS: permeability surface. PVTT: portal vein tumor thrombus.
Table 4 The correlation efficient (rs) between PVTT CT
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processing of raw data.
The change of VEGF protein Expression in PVTT before
and after Endostar treatment
Our study found that post-treatment VEGF protein Ex-
pression in portal vein VX2 tumor thrombus was signifi-
cantly lower in Endostar group than control group. There
are several potential reasons for the reduction of VEGF
protein Expression in portal vein VX2 tumor thrombus
after Endostar treatment. Once reaching certain size, VX2
tumor thrombus can secrete VEGF through autocrine or
paracrine signaling pathway, which acts on vascular endo-
thelial cells to form the tumor microvasculature and sup-
port tumor growth [10]. In this study, two weeks after the
transplantation of VX2 tumor into the rabbit portal vein,
the tumor cells have already grown up, and showed high
degree of VEGF protein expression in PVTT from immu-
nohistochemistry assay before Endostar treatment. Endo-
star is a broad-spectrum anti-angiogenic drug, binds to
the VEGF receptor on endothelial cells and blocks the an-
giogenic effect of VEGF. Endostar works directly on the
microvascular endothelial cells of the tumor by affecting
the endothelial growth factor receptor (VEGFR) to pre-
vent the binding between VEGF and endothelial cell, and
block the effect of VEGF. In addition, Endostar can alsoTable 3 PVTT perfusion parameters after treatment in






TBF (ml/100 ml/min) 380.76 ± 13.89 274.55 ± 26.99 18.77 0.00
TBV (ml/100 ml) 20.08 ± 4.05 7.11 ± 0.45 7.35 0.01
PS (ml/100 ml/min) 47.57 ± 5.90 32.68 ± 2.99 12.18 0.00
Note: TBF: tissue blood flow; TBV: tissue blood volume; PS: permeability
surface; PVTT: portal vein tumor thrombus.lower VEGF mRNA and protein expression, directly
blocks the VEGF receptor signal transduction, thereby
inhibits VEGF-mediated endothelial cell migration and
angiogenesis [11]. After Endostar treatment, the num-
ber of microvessel within the tumor significantly de-
creased; consequently the oxygen and nutrient supply
to the tumor tissue are reduced, leading to apoptosis
of tumor cells and reduction of VEGF protein expres-
sion from tumor cells. Therefore, in this study the
PVTT VEGF protein expression significantly declined
after Endostar treatment.
The change of CT perfusion parameters before and after
Endostar treatment
This study found that CT perfusion parameters of PVTT
significantly decreased after endostar treatment. There are
several potential reasons for this observation. At the de-
velopment of PVTT, tumor angiogenesis was significantly
increased. Between the large numbers of immature vascu-
lar endothelial cells, the connections were loose and the
gaps were larger than normal. Part of tumor vessel wall
even did not have endothelial cells, leading to increased
vascular permeability. Therefore, PVTT perfusion param-
eters were higher at baseline than after the endostarperfusion results and VEGF expression by treatment
group (n = 6)
Group TBF TBV PS
Control 0.971 (p < 0.05) 0.941 (p < 0.05) 0.926 (p < 0.05)
Endostar
(Post-treatment)
0.986 (p < 0.05) 0.971 (p < 0.05) 0.883 (p < 0.05)
Saline
(Post-treatment)
0.986 (p < 0.05) 0.812 (p < 0.05) 0.986 (p < 0.05)
Note: TBF: tissue blood flow; TBV: tissue blood volume; PS: permeability surface;
PVTT: portal vein tumor thrombus; CT: Computed Tomography; VEGF: Vascular
Endothelial Growth Factor.
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certain abnormal characteristics of the tumor angiogen-
esis through a process named "vascular normalization"
(maturation of the immature tumor blood vessels and the
reduction of immature blood vessels), to reduce the perme-
ability of tumor blood vessels. In addition, Endostar can
remove less differentiated blood vessels, and retain differen-
tiated and mature blood vessels. In this study, CT perfusion
imaging demonstrated differences of tumor perfusion pa-
rameters before and after endostar treatment; the finds pro-
vided valuable experimental data for clinical evaluation the
treatment effects of PVTT.The relationship between PVTT CT perfusion results and
VEGF protein expression
In this study, PVTT CT perfusion parameters were
shown positively correlated with the expression of
VEGF, which may be due to the following reasons. The
tumor growth, development, metastasis and prognosis
are closely related to the functional status of neovascu-
larization inside the tumor. Due to incomplete vessel
walls, large gaps between adjacent vascular endothelial
cells, the permeability of the new blood vessels is in-
creased. Tumor cells can easily move in or out of the
blood vessels, resulting in distant metastasis. Therefore,
tumor neovascularization was an important indicator for
tumor growth, metastasis, and degree of malignancy [13].
Neovascularization cannot be observed directly from the
image, but can cause the changes of blood volume, perfu-
sion volume, and capillary permeability. MSCT perfusion
imaging is essentially to study the perfusion characteristics
within the tumor, and can quantify the tissue blood
flow, tissue blood volume, and microvascular perme-
ability within a unit of tumor tissue, thus indirectly
reflect the functional status of the tumor vasculature
[14,15]. The speed of tumor growth is determined in-
directly by the vascular endothelial cells, while the pro-
liferation of endothelial cells mainly depends on VEGF.
Tumor cells can synthesize and periodically secrete
VEGF, which then binds with VEGF receptors on endo-
thelial cells to promote tumor angiogenesis [16]. VEGF
also has heparin binding activity, binds to receptor-2
and release various growth factors and cytokinesto
stimulate tumor growth and promote endothelial cell
proliferation and tumor angiogenesis [17]. When the
contrast agentspass through the tumor vasculature, ex-
travasation can be easily seen. The incomplete tumor
vascular endothelium can cause the elevation in CT
perfusion values. Meanwhile, due to the increase in the
number of new blood vessels within the tumor, the
blood supply is abundant, and the contrast agent is
easy to go into the tumor tissue, resulting in the in-
creased perfusion parameters.Conclusions
In summary, as a targeted anti-VEGF drug, Endostar re-
duces the VEGF protein expression within PVTT. MSCT,
as a functional imaging modality, can obtain and analyze
PVTT perfusion parameters (TBF, TBV, PS), indirectly es-
timate understand the extent of VEGF protein expression
in PVTT, thus define the status of tumor angiogenesis and
provide valuable information for evaluating the efficacy of
PVTT treatment. Our study is still in the animal experi-
mental stage. Given the high radiation exposure from CT
perfusion scan, its role in the evaluation of PVTT treat-
ment should be further investigated in clinical research.
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